SriniVas Sadda1, Nancy M Holekamp2, David Sarraf3, Adel Ebraheem4, Wenying Fan4, Lauren Hill5, Steve Blotner5, Galin Spicer5, Shamika Gune5. 1. Doheny Eye Institute, 625 S Fair Oaks Ave, Suite 280, Pasadena, CA, 91105, USA. ssadda@doheny.org. 2. Pepose Vision Institute, Chesterfield, MO, USA. 3. UCLA Stein Eye Institute, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA. 4. Doheny Eye Institute, 625 S Fair Oaks Ave, Suite 280, Pasadena, CA, 91105, USA. 5. Genentech, Inc., South San Francisco, CA, USA.
Abstract
PURPOSE: To evaluate the relationship between retinal fluid location, amount/severity, and vision with ranibizumab-treated neovascular age-related macular degeneration (nAMD). METHODS: In the phase 3 HARBOR trial (NCT00891735), treatment-naive patients with nAMD received ranibizumab 0.5 or 2.0 mg through month 24. This post hoc analysis included eyes with subretinal fluid (SRF) and/or intraretinal fluid (IRF) at screening, baseline, or week 1, and optical coherence tomography data at months 12 and 24 (n = 917). Outcomes were best-corrected visual acuity (BCVA) change from baseline and proportion of eyes with 20/40 or better vision at months 12 and 24. Eyes were stratified by the location, amount, and/or severity of fluid. RESULTS: At baseline, 86% and 63% of eyes had SRF and IRF, respectively. Among eyes with residual SRF, mean BCVA gains at each time point were greater in eyes with central versus noncentral SRF; location did not affect the odds of having 20/40 or better vision over 24 months. Eyes with 20/40 or better BCVA at month 12 had significantly lower SRF thickness versus eyes with worse vision; however, no difference was apparent at month 24. Vision was comparatively worse in eyes with residual IRF at months 12 and 24; location and severity did not appear to affect this outcome. CONCLUSION: Residual IRF was associated with worse vision outcomes, regardless of location/severity, whereas, despite continued treatment, residual SRF was not associated with worse vision outcome at 24 months, regardless of location/thickness. These data suggest complex relationships between residual fluid, severity, and vision.
PURPOSE: To evaluate the relationship between retinal fluid location, amount/severity, and vision with ranibizumab-treated neovascular age-related macular degeneration (nAMD). METHODS: In the phase 3 HARBOR trial (NCT00891735), treatment-naive patients with nAMD received ranibizumab 0.5 or 2.0 mg through month 24. This post hoc analysis included eyes with subretinal fluid (SRF) and/or intraretinal fluid (IRF) at screening, baseline, or week 1, and optical coherence tomography data at months 12 and 24 (n = 917). Outcomes were best-corrected visual acuity (BCVA) change from baseline and proportion of eyes with 20/40 or better vision at months 12 and 24. Eyes were stratified by the location, amount, and/or severity of fluid. RESULTS: At baseline, 86% and 63% of eyes had SRF and IRF, respectively. Among eyes with residual SRF, mean BCVA gains at each time point were greater in eyes with central versus noncentral SRF; location did not affect the odds of having 20/40 or better vision over 24 months. Eyes with 20/40 or better BCVA at month 12 had significantly lower SRF thickness versus eyes with worse vision; however, no difference was apparent at month 24. Vision was comparatively worse in eyes with residual IRF at months 12 and 24; location and severity did not appear to affect this outcome. CONCLUSION: Residual IRF was associated with worse vision outcomes, regardless of location/severity, whereas, despite continued treatment, residual SRF was not associated with worse vision outcome at 24 months, regardless of location/thickness. These data suggest complex relationships between residual fluid, severity, and vision.
Authors: Peter J Kertes; Ivan J Galic; Mark Greve; R Geoff Williams; Emmanouil Rampakakis; Andrea Scarino; Tom Sheidow Journal: Ophthalmology Date: 2019-01-21 Impact factor: 12.079
Authors: Charles C Wykoff; Daniel E Croft; David M Brown; Rui Wang; John F Payne; Lloyd Clark; Nizar Saleh Abdelfattah; SriniVas R Sadda Journal: Ophthalmology Date: 2015-09-29 Impact factor: 12.079
Authors: Christina J Flaxel; Ron A Adelman; Steven T Bailey; Amani Fawzi; Jennifer I Lim; G Atma Vemulakonda; Gui-Shuang Ying Journal: Ophthalmology Date: 2019-09-25 Impact factor: 12.079
Authors: Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2007-04 Impact factor: 5.258
Authors: Brandon G Busbee; Allen C Ho; David M Brown; Jeffrey S Heier; Ivan J Suñer; Zhengrong Li; Roman G Rubio; Phillip Lai Journal: Ophthalmology Date: 2013-01-23 Impact factor: 12.079
Authors: Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2009-04-18 Impact factor: 5.258